BioSpace News Archive

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced its decision to discontinue development of suvodirsen for patients with Duchenne muscular dystrophy (DMD) who have mutations amenable to exon 51 skipping, based on its interim analysis of the Phase 1 open-label extension (OLE) study.

Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced today that Robin L. Smith, MD, MBA has been appointed to its Board of Directors.

Mauna Kea Technologies inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy platform, today announced a strategic equity investment of 7.5 million euro by Johnson & Johnson Innovation – JJDC, Inc..

On 16 December, the world’s leading healthcare ecosystem platform, Ping An Healthcare and Technology Company Limited announced that the Company and Thailand’s largest healthcare group Bangkok Dusit Medical Services jointly launched the overseas video consultation service for second opinions.

NeuroVive Pharmaceutical AB announced that it has fully and finally settled the dispute with CicloMulsion AG regarding certain pharmaceutical technology.

Polydex Pharmaceuticals Limited announces 3rd quarter financial results.

Danaher Corporation announced the preliminary results of its previously announced offer to holders of shares of Danaher common stock to exchange their shares of Danaher common stock for shares of common stock of Envista Holdings Corporation owned by Danaher.

ChromaDex Corp. (NASDAQ:CDXC) announced today that Nutritional Outlook®, a leading publication for the nutraceuticals industry, recently awarded ChromaDex the 2019 “Best of Industry Award,” in the “Ingredient Supplier” category, for Niagen® (nicotinamide riboside).

Humana Inc. (NYSE: HUM) today announced it has signed a definitive agreement to acquire privately held Enclara Healthcare (Enclara), one of the nation’s largest hospice pharmacy and benefit management providers, from Consonance Capital Partners and Enclara management.

Eli Lilly and Company (NYSE: LLY) has announced a global commercialization agreement to integrate DexCom, Inc. (NASDAQ: DXCM) products into Lilly’s personalized diabetes management system, currently in development to advance the treatment of diabetes